Biotechnology, Healthcare, and Research by Gilead Sciences
157.37
3.83
2.49 %
At close
10/15
USD
Daily range
156.04
160.49
160.49
Weekly range
146.40
153.76
153.76
What's behind Gilead Sciences's latest 3.6% stock surge?
Gilead Sciences, Inc. (GILD) surged 3.60% after posting a strong second-quarter revenue increase and advancing its oncology pipeline through a major collaboration with Vir Biotechnology. The move ...
Gilead Sciences shares technical analysis: Pullback signals pressure as sellers dominate near term
Gilead Sciences (GILD) stock is trading at $130.32, down 3.65% for the latest session. The move leaves the stock positioned below its short- and long-term moving ...
Gilead Sciences shares drop more than 3% after positive HIV sales outlook fails to lift sentiment
Gilead Sciences, Inc. (GILD) dropped 3.35% after selling pressure dominated intraday action, even as upbeat second-quarter earnings and raised full-year HIV revenue guidance set a positive ...
Gilead Sciences stock edges lower to $130.30 as CHMP positive opinion on mTNBC regimen announced, Gilead Sciences
Gilead Sciences received a positive opinion from the CHMP for its combination regimen in PD-(L)1-positive first-line metastatic triple-negative breast cancer.If approved, patients with PD-(L)1 ...
Gilead Sciences stock trades at weekly lows after AIDS 2026 HIV update
Gilead Sciences announced it will present new HIV research at AIDS2026.The company stated these presentations will cover prevention, treatment, and cure. Long-term data for its twice-yearly HIV ...
Why is Gilead Sciences stock down today? Price tests multi-week lows with reversal risk
Gilead Sciences (GILD) stock is trading at $129.78, down 3.76% on the day and settling near the session’s lows. The price remains below all key moving averages, ...
FDA approval for mTNBC therapy cannot lift Gilead Sciences stock as bearish trend persists
Gilead Sciences received FDA approval for its treatment for first-line metastatic triple-negative breast cancer.Gilead Sciences stated the news yesterday. The company referred to recent coverage ...
Gilead Sciences edges higher to $125.14 as FDA approves new metastatic breast cancer therapy, Gilead Sciences
Gilead Sciences said the U.S. FDA approved its treatment for first-line metastatic triple-negative breast cancer.According to Gilead Sciences, the therapy marks a new backbone option for people ...
Gilead Sciences stock price forecast: $120.19 support in focus as GILD slides 1.82%
Gilead Sciences (GILD) stock is trading at $123.17, posting a daily decline of 1.82%. The price remains below its key moving averages, reflecting short-term and ...
Gilead Sciences stock edges lower to $124.30 as FDA reviews new once-weekly HIV PrEP, Gilead Sciences announces
Gilead Sciences said the U.S. FDA has accepted its filing for an investigational once-weekly oral option for HIV prevention as pre-exposure prophylaxis.If approved, this formulation could become ...
Gilead Sciences stock continues downward trend amid oversold signals and resistance at 132.29
Gilead Sciences is sharing personal stories from hepatitis B carriers in Asian-Pacific nations to raise awareness about the link between HBV and liver cancer.Participants reflect on what they wish ...
Gilead Sciences stock trades down at $128.10 after positive HIV trial update, Gilead Sciences reports
Gilead Sciences announced positive topline results from a Phase 3 study of an investigational long-acting oral HIV treatment in collaboration with Merck.The announcement was made today. Gilead ...
Gilead Sciences stock trades up with weak intraday momentum amid HIV partnership expansion
Gilead Sciences said access to long-acting HIV prevention medication is accelerating because of the leadership of the South African government and the Global Fund.The company said this effort ...
Gilead Sciences stock drops 2.59% as collaboration with WHO on kala-azar elimination renewed, Gilead Sciences
Gilead Sciences held a high-level meeting with the WHO on the sidelines of the 79th World Health Assembly to announce the five-year renewal of their collaboration to accelerate progress toward ...
